Phase II study of oxaliplatin based regimen in relapsed colon cancer patients treated with oxaliplatin based adjuvant
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2019
Price : $35 *
At a glance
- Drugs Oxaliplatin (Primary) ; Fluoropyrimidine derivatives
- Indications Colon cancer; Colorectal cancer
- Focus Therapeutic Use
- Acronyms INSPIRE
- 06 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 19 Dec 2018 Planned number of patients changed from 105 to 50.
- 19 Dec 2018 Planned End Date changed from 31 Aug 2017 to 31 Mar 2022.